Midstage trial of Boehringer's anti-clot drug begins

12/10/2007 | Yahoo!

German drugmaker Boehringer Ingelheim GmbH on Sunday announced it has started a midstage trial to evaluate the safety and efficacy of its experimental drug dabigatran etexilate for patients with acute coronary syndrome. Dabigatran was found as effective as Sanofi-Aventis' Lovenox in preventing blood clots after hip surgery, and is expected to compete against Bayer's new drug rivaroxaban.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Fort Worth, TX
Senior Scientist - Cell Engineering Group
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC